News

Passage Bio Unveils Exciting Data on PBFT02 for Neurodegeneration

Passage Bio Unveils Exciting Data on PBFT02 for Neurodegeneration

Introduction to PBFT02 and Its Promise

Exciting advancements in genetic medicine are spotlighted as Passage Bio, Inc. (Nasdaq: PASG), a pioneering company dedicated to combatting neurodegenerative diseases, shares groundbreaking preclinical and interim clinical findings at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress. This innovative data centers around PBFT02, an AAV gene therapy designed to elevate progranulin levels in patients suffering from frontotemporal dementia with GRN mutations (FTD-GRN).

Preclinical Findings and Clinical Implications

Recent studies highlight the effectiveness of the AAV1 vector in elevating human progranulin levels in the cerebrospinal fluid (CSF), showcasing a notable improvement over AAV5 and the AAVhu68 variant during extended preclinical trials. Significant positive results emerged from experiments using Grn knockout mice, where PBFT02 not only lessened neuroinflammation and improved lysosomal histopathology but also showed a well-distributed vector throughout the nervous systems in non-human primates (NHPs).

Key Highlights from the Oral Presentation

During the ESGCT conference, which spanned from late October, members of Passage Bio delivered comprehensive insights into PBFT02’s potential. Dr. Sue Browne, the Chief Scientific Officer, presented data that underscores both the robust preclinical results and interim outcomes from the ongoing upliFT-D clinical trial.

Significant Outcomes from Research

The findings emphasized that PBFT02 effectively improved lysosomal functionality and reduced inflammation within the central nervous system, crucial for combating the neurodegenerative aspects of diseases like FTD. Furthermore, the biodistribution studies illustrated how ICM administration of PBFT02 led to profound vector availability throughout the nervous system, effectively targeting affected cortical and sub-cortical regions and demonstrating a strong safety profile.

Promising Interim Data

The interim data being presented demonstrated that Dose 1 of PBFT02 was generally well-received by patients in Cohort 1 of the upliFT-D study, with prolonged elevations in CSF progranulin levels persisting for up to 12 months after administration. These promising results reinforce the hypothesis that higher levels of progranulin yield additional therapeutic benefits.

Company Vision and Future Directions

Will Chou, M.D., the president and CEO of Passage Bio, expressed enthusiasm about the potential of PBFT02 and the preclinical findings that bolstered their clinical strategies. The company is focused on elevating progranulin levels, a strategy that not only addresses symptoms but also aims to alter the disease's progression itself.

Broader Applications in Neurodegenerative Diseases

Passage Bio remains committed to exploring the therapeutic implications of PBFT02 beyond FTD, looking into its potential applications across various neurodegenerative conditions that might benefit from elevated progranulin levels. With continued research and promising clinical data, the future looks bright for PBFT02.

Conclusion and Commitment to Innovation

As Passage Bio advances through clinical development, its mission to enhance the lives of patients with neurodegenerative diseases remains paramount. The dedication to research and innovation aims to create effective therapies that alter the course of these debilitating conditions, providing hope for many families.

Frequently Asked Questions

What is PBFT02?

PBFT02 is an AAV gene therapy developed by Passage Bio, aimed at treating frontotemporal dementia by elevating progranulin levels in the CSF.

What are the recent findings presented by Passage Bio?

Recent presentations highlighted significant preclinical and interim clinical data showing PBFT02's efficacy in increasing CSF progranulin levels and improving lysosomal function.

How does PBFT02 aim to address neurodegenerative diseases?

By utilizing an AAV1 vector to elevate progranulin levels in the central nervous system, PBFT02 aims to restore lysosomal function and combat the progression of neurodegenerative diseases.

What are the next steps for Passage Bio with PBFT02?

The company plans to further its clinical trials and explore additional therapeutic applications of PBFT02 for other neurodegenerative conditions.

Who can benefit from PBFT02?

Patients diagnosed with frontotemporal dementia and potentially other neurodegenerative diseases might benefit from PBFT02, as it targets the underlying pathology of these conditions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 248

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 348

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 90

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 488

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming Energy Management with ETB Controller from Energy Toolbase

Updated Category News Views 72

Energy Toolbase Reveals New Branding for Energy Management System Energy Toolbase has made a significant leap in the energy management sector by rebranding its energy storage control software, Acumen EMS™, to ETB Controller. This transformation marks a pivotal moment for the company as they strive to clarify the product's purpose and enhance user understanding. The ETB...

Continue Reading
FICO Achieves Silver Recognition in Analytics at 2024 IT Awards

Updated Category News Views 37

FICO Receives Silver Award for Analytics in 2024 IT Awards In a notable recognition of excellence, global analytics software leader FICO has earned the Silver Award in the Analytics category at the prestigious IT Awards for this year. Organized by Vogel IT-Media, these awards celebrate remarkable achievements and innovations within the IT sector, reflecting the industry's...

Continue Reading
Opera Limited Announces $0.40 Cash Dividend for Shareholders

Updated Category News Views 124

Opera Limited Announces Cash Dividend Opera Limited (NASDAQ: OPRA), a prominent developer in the browser market, has recently shared exciting news regarding its dividend program. The company’s Board of Directors has approved a semi-annual cash dividend of $0.40 per share. This dividend will be available to shareholders holding the company’s ordinary shares and...

Continue Reading
Revolutionizing IT Operations: JetPatch Unveils Version 5.0

Updated Category News Views 162

Revolutionizing IT Operations: JetPatch Unveils Version 5.0 New Capabilities Supercharge Patch Management and Streamline Enterprise Efficiency JetPatch, a leading innovator in enterprise IT operations, has revealed its most significant software release to date, which marks a major step forward in how organizations manage their servers, endpoints, and agents throughout...

Continue Reading
Revolutionizing Customer Billing: Ericsson and Wipro's Success

Updated Category News Views 97

Transformed Billing Experience for Odido Customers Ericsson (NASDAQ: ERIC) and Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) have successfully reshaped the billing landscape for Odido's mobile customers in the Netherlands. By adopting the cloud-native Ericsson Billing platform, hosted on Amazon Web Services (AWS), Odido can now offer cutting-edge 5G services along...

Continue Reading